Results 141 to 150 of about 1,236,573 (326)
Molecular Oncology, EarlyView.Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece +18 more
wiley +1 more source
Evolution of left-right asymmetry in the sensory system and foraging behavior during adaptation to food-sparse cave environments. [PDF]
BMC Biol, 2022 Fernandes VFL +3 more
europepmc +1 more source
Correlation of visual system biomarkers with motor-sensory deficits in experimental autoimmune encephalomyelitis-optic neuritis [PDF]
, 2023 Benjamin W. Elwood +4 more
openalex +1 more source
Molecular Oncology, EarlyView.CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir +12 more
wiley +1 more source
Sex-specific evolution of a Drosophila sensory system via interacting cis- and trans-regulatory changes. [PDF]
Evol Dev, 2022 Luecke D, Rice G, Kopp A.
europepmc +1 more source
Biomimetic Emotional Learning Agents [PDF]
, 2005 This extended abstract proposes a type of AI agent comprised of: an autonomous real-time control system,\ud low-level emotional learning (including a simple\ud knowledge base that links homeostatic/innate drives to sensory perception states), and a novel
Kenyon, Samuel H.
core
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source